Welcome to our dedicated page for Quest Diagnostics news (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics stock.
Quest Diagnostics Incorporated reports developments in diagnostic information services, laboratory testing and related healthcare data offerings. Company news commonly covers financial results, guidance, clinical testing activity, consumer access through questhealth.com and MyQuest, and advanced diagnostics such as Quest AD-Detect blood tests for Alzheimer’s disease and Haystack MRD ctDNA testing for oncology research.
Updates also include health system collaborations, Co-Lab Solutions activity, clinical trial and research partnerships, AI-enabled patient tools, board and executive appointments, dividends, share repurchases, debt financing and shareholder voting matters.
Summary not available.
Summary not available.
Quest Diagnostics (NYSE: DGX) announced a definitive agreement to acquire its joint venture partners' interests in Mid America Clinical Laboratories (MACL), the largest independent clinical lab provider in Indiana. This all-cash equity transaction aims to optimize diagnostic service delivery in the state. Following the acquisition, Quest will wholly own MACL's Indianapolis lab and about 50 patient service centers. The deal also includes long-term agreements for hospital lab services. Completion is expected in Q3 2020, pending regulatory review.